"We recently purchased the FLEXcyte-96 system through the NIH shared instrument grant (S10) program to be used by a diverse group of researchers who use cultured heart cells to study genetic and other cardiac disorders or who need to test lead compounds for cardiac toxicity. We have been thoroughly satisfied by the performance of the instrument and have been pleased with the great support from Nanion. The 96-well format enables critically important replication and the ability to conduct multiple simultaneous experiments. We are now exploring use of the instrument to interrogate other types of contractile cells. Given the enthusiasm from multiple investigators, we are going to purchase a second instrument."
"The FLEXcyte brings another dimension to iPS-derived cardiomyocyte based assays. Measuring contractility in such a direct and easy way allows us to understand the cell functionality better and will help us in both our product development and safety pharmacology research.”"
"We were very pleased with our choice to engage innoVitro’s contractility service. The studies using human iPSC-derived cardiomyocytes were tailored to our needs to provide results comparable to already existing (in house) data and the fast execution followed by a comprehensive study report completed the service perfectly."